Dynamic PET CT as a Tool for Treatment Efficacy Monitoring in Lung Cancer

Lung Cancer Clinical Trial

Official title:

Dynamic PET CT as a Tool for Treatment Efficacy Monitoring in Lung Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02505685
• Other study ID #: 0618-14-RMC
• Status: Active, not recruiting
• Phase: N/A
• First received: July 2, 2015
• Last updated: November 17, 2016
• Start date: June 2015
• Est. completion date: July 2020

Study information

• Verified date: October 2016
• Source: Rabin Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: Israel: Ministry of Health
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to evaluate the use of Dynamic PET/CT as a tool to assess disease response to anti-cancer therapy in Lung Cancer patients.

Description:

Background:

Lung cancer is a devastating disease in which the response for first line therapy is only 30%. Evaluating response is performed normally by a CT or PET-CT scans after 2-3 cycles of therapy, thus, lack of response is been evaluated only after the patient has been treated following significant amount of therapy, which is inefficient in 70% of cases.

Therefore, there is an urgent need to develop tools that might predict response to therapy during the early course of therapy; Most valuable will be before or after the first cycle of therapy. For that reason, the investigators aim in this study to evaluate the use of Dynamic PET-CT as a tool to assess disease response to anti-cancer therapy in Lung Cancer patients.

Objectives:

1. To assess the feasibility of baseline Dynamic PET-CT as a tool for assessing response for anti-cancer therapy in Lung Cancer patients.

2. To predict early response to treatment as soon as after 1 cycle of therapy by dynamic and static PET-CT.

3. To correlate Dynamic PET-CT with survival/disease free survival

Method:

200 advanced lung cancer patients will be enrolled over 3 years in a single institute, single arm study at Rabin Medical Center, Beilinson Hospital.

Patients will be evaluated by a Dynamic PET-CT protocol: before initiation of therapy, 7-14 days after the first therapy cycle, 3 months after initiation of therapy and 6 months after the first therapy cycle. In addition, non-invasive biomarkers that are routinely measured including protein markers (CEA- Carcinoembryonic Antigen, CYFRA21- Cytokeratin 19 Fragment, NSE- Neuron Specific Enolase) will be assessed in this trial.

Disease response will be evaluated by Response Evaluation Criteria In Solid Tumors (RECIST criteria).

Additional PET-CT will not increase radiation dose significantly. The mean estimated radiation dose for a limited CT of the chest is about 14 mSv (i.e., 7mSv for limited diagnostic CT and FDG ([18F]-fluorodeoxyglucose), each). The dynamic stage will add radiation dose of about 0.3mSv. Of note, the significance of adding radiation dose is less of importance with regard to treatment of patients with aggressive cancer.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 200
• Est. completion date: July 2020
• Est. primary completion date: July 2018
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 95 Years

Eligibility

Inclusion Criteria:

• Age > 18 years.

• Lung cancer, stage 4

• Patients are planned to be treated by a systemic anti-cancer therapy.

• A define lesion for imaging.

• Able and willing to sign an informed consent form.

• First line therapy or at least 6 weeks after previous line of therapy

Exclusion Criteria:

• Pregnant or lactating women.

• Anti cancer therapy within the last 6 weeks before enrollment.

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

Locations

Country	Name	City	State
Israel	Rabin Medical Center	Petach Tikva

Sponsors (1)

Lead Sponsor	Collaborator
Rabin Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Compare baseline PET-CT with PET-CT after 7-14 days.		12 months	No
Secondary	Evaluate disease-free survival (DFS) in lung cancer by using dynamic PET-CT.		12 months	No
Secondary	Evaluate overall survival rate (OS) in lung cancer by using dynamic PET-CT.		12 months	No
Secondary	Measuring response to treatment by PET-CT.		12 months	No